Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Depreciation & Amortization (CF): 2013-2024

Historic Depreciation & Amortization (CF) for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to $17.6 million.

  • ImmunityBio's Depreciation & Amortization (CF) fell 11.31% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year decrease of 12.14%. This contributed to the annual value of $17.6 million for FY2024, which is 5.18% down from last year.
  • ImmunityBio's Depreciation & Amortization (CF) amounted to $17.6 million in FY2024, which was down 5.18% from $18.5 million recorded in FY2023.
  • Over the past 5 years, ImmunityBio's Depreciation & Amortization (CF) peaked at $18.5 million during FY2023, and registered a low of $12.7 million during FY2020.
  • Its 3-year average for Depreciation & Amortization (CF) is $18.1 million, with a median of $18.3 million in 2022.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first declined by 9.28% in 2020, then increased by 28.25% in 2022.
  • Yearly analysis of 5 years shows ImmunityBio's Depreciation & Amortization (CF) stood at $12.7 million in 2020, then climbed by 11.77% to $14.2 million in 2021, then rose by 28.25% to $18.3 million in 2022, then climbed by 1.38% to $18.5 million in 2023, then declined by 5.18% to $17.6 million in 2024.